Ipamorelin Reverses Steroid-Induced Bone Loss in Adult Rats Over 3 Months
Three months of ipamorelin treatment counteracted methylprednisolone-induced decreases in bone formation and bone mineral content in adult rats, demonstrating sustained bone-protective effects against steroid damage.
Quick Facts
What This Study Found
Three months of ipamorelin (SC injection) counteracted methylprednisolone-induced decreases in bone formation rate, bone mineral content, and partially preserved skeletal muscle mass in adult female rats.
Key Numbers
How They Did This
Animal study in 8-month-old female rats. Groups treated for 3 months with: vehicle, methylprednisolone alone, ipamorelin alone, or methylprednisolone + ipamorelin. Bone formation rate, bone mineral content, and muscle mass measured.
Why This Research Matters
Steroid-induced osteoporosis affects millions of patients on chronic corticosteroids. A GH secretagogue that maintains bone formation during steroid therapy could prevent fractures and disability.
The Bigger Picture
The clinical need for bone protection during steroid therapy is enormous — from autoimmune diseases to transplant medicine to chronic lung disease. Ipamorelin's bone-sparing effect in this context is clinically highly relevant.
What This Study Doesn't Tell Us
Rat study. Three months in rats is relatively long but may not predict lifetime steroid use effects in humans. Adult female rats used; effects may differ by sex and age.
Questions This Raises
- ?Would ipamorelin prevent steroid-induced fractures in human patients?
- ?Does the bone protective effect persist after ipamorelin discontinuation?
- ?Can ipamorelin be used with any steroid, or is the protection steroid-specific?
Trust & Context
- Key Stat:
- 3-month protection Ipamorelin maintained bone formation and mineral content through 3 months of concurrent steroid treatment in adult rats
- Evidence Grade:
- Preliminary but clinically relevant animal evidence with long treatment duration and multiple bone outcome measures.
- Study Age:
- Published in 2001. Ipamorelin's bone-protective effects during steroid therapy remain relevant for clinical development.
- Original Title:
- The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats.
- Published In:
- Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 11(5), 266-72 (2001)
- Authors:
- Andersen, N B, Malmlöf, K(2), Johansen, P B(4), Andreassen, T T, Ørtoft, G, Oxlund, H
- Database ID:
- RPEP-00642
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Can ipamorelin prevent steroid-induced bone loss?
In this 3-month rat study, yes. Ipamorelin maintained bone formation and mineral content that methylprednisolone was destroying. This addresses one of the most common and serious side effects of chronic steroid use.
Why is this important for patients on steroids?
Millions take steroids for asthma, arthritis, and other conditions. Bone loss leading to fractures is a major complication. If ipamorelin can prevent this while patients continue their necessary steroid therapy, it would significantly improve their quality of life.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00642APA
Andersen, N B; Malmlöf, K; Johansen, P B; Andreassen, T T; Ørtoft, G; Oxlund, H. (2001). The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats.. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 11(5), 266-72.
MLA
Andersen, N B, et al. "The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats.." Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2001.
RethinkPeptides
RethinkPeptides Research Database. "The growth hormone secretagogue ipamorelin counteracts gluco..." RPEP-00642. Retrieved from https://rethinkpeptides.com/research/andersen-2001-the-growth-hormone-secretagogue
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.